Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone Meeting Abstract

  


Authors: Robert, C.; Larkin, J.; Ascierto, P. A.; Long, G. V.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; Wagstaff, J.; Chesney, J.; Hogg, D.; Bechter, O.; Márquez-Rodas, I.; Pavlick, A. C.; Walker, D.; Bhore, R.; Postow, M. A.; Wolchok, J. D.
Abstract Title: Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
Meeting Title: 42nd ESMO Congress (ESMO 2017)
Journal Title: Annals of Oncology
Volume: 28
Issue: Suppl. 5
Meeting Dates: 2017 Sep 8-12
Meeting Location: Madrid, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2017-09-01
Start Page: mdx377
Language: English
ACCESSION: WOS:000411324003125
PROVIDER: wos
DOI: 10.1093/annonc/mdx377
Notes: Meeting Abstract: 1213O -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Michael Andrew Postow
    362 Postow
Related MSK Work